More patent-opposition on Gilead’s hepatitis C drug, sofosbuvir - (Business Line via NewsPoints Desk)

  • Business Line reported Monday that non-government organisation Sankalp Rehabilitation Trust has filed a pre-grant opposition on Gilead Sciences' hepatitis c drug sofosbuvir in the Delhi patent office.
  • Earlier last month, the Patent office rejected Gilead's patent application on the drug, on the grounds that it did not exhibit greater efficacy.
  • Later in the month, the Delhi High Court set aside the patent office's order that rejected the application, in effect returning proceedings for a fresh round of hearings on the patent application.
  • Sankalp's opposition is the fourth opposition against Gilead's base patent application, with others including oppositions by I-Mak together with the Delhi Network of Positive People, Natco Pharma and BDR Pharmaceuticals.

To read more NewsPoints articles, click here.